Global News

Danaher to acquire Cepheid for $4B

Tuesday, September 13, 2016

Danaher has entered into a definitive merger agreement with Cepheid pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion including indebtedness and net of acquired cash.  

[Read More]

The key to drug development success is collaboration

Monday, September 12, 2016

The Pulse on Study Conduct by Elizabeth Weeks-Rowe

Bridging drug discovery to drug development is a fundamental tenet in clinical research conduct that requires strategic collaboration. Successfully bridging investigational site relationship discovery to site development requires the same critical collaboration from study startup to study conclusion, and all pivotal points in between. The investigational site/study team dynamic will positively or negatively drive site performance in a clinical trial, and successful stewardship is key to this outcome.

[Read More]

Arrowhead doses first patient with hepatitis B in phase I/II ARC-521study

Thursday, September 8, 2016

Arrowhead Pharmaceuticals has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing phase I/II study of ARC-521, the company’s second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. To date 24 healthy volunteers have been treated in the study, and the drug safety committee (DSC) approved initiation of the MAD after a planned review of safety data from cohort 3 of the healthy volunteer portion of the study. The MAD is designed to evaluate the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV.

[Read More]